Vaccine induced thrombocytopenia(VITT) is a rare but serious disease. Within the framework of kobe – 19 vaccination, it has received many news and social media comments. The newly discovered disease is caused by the immune system’s response to the Kobe – 19 vaccine, so it is different from other types of Kobe disease. The most common are Chidox1-NCoV-19(AstraZeneca) and Ad26.COV2.S(Johnson&Johnson). Both vaccines use viral vectors(the mRNA vaccine of Moderna does not use this vector). Pathologically, this is very similar to autoimmune heparin induced thrombocytopenia(HIT). Vaccine induced thrombocytopenia is due to autoantibodies to platelet factor 4, which stimulates platelet thrombosis. Typically these clots are in the brain or abdomen.

For every 1 million vaccines provided by VITT, 4-6 people will be vaccinated. Reduce the risk after the second administration. Although the initial mortality rate of the patients was 50%, most of them recovered today after rapid discovery and proper treatment. Although there is no clear risk factor, it may be more common under the age of 50. In the past, blood necrosis(such as deep vein thrombosis) or other non immune blood diseases were not risk factors.

although the risk is low, it does make many people give up this kind of vaccination, decide to vaccinate with mRNA vaccine, or just use it as a reason not to vaccinate. This has prompted many public health experts to promote marketing campaigns to counter the negative impact of talking about how low the risk of death from COVID infection is. These strategic and social media comments suggest something, such as the possibility of being hit by lightning is far greater than the possibility of being bruised by vaccines.

The usual symptoms are persistent and severe headache, stomachache, low back pain, nausea and vomiting, visual changes, changes in mental status, neurological symptoms, dyspnea, leg pain, edema and/or bleeding symptoms within 4 to 42 days after vaccination. People with this condition need to measure their platelet levels and D-dimer, as well as possible clots. The diagnostic criteria were venous or arterial thrombosis, frequent thrombocytopenia, and positive ELISA evaluation of hemoglobin induced thrombocytopenia after novel coronavirus vaccination in the past 42 days.

Due to the severity of the symptoms and possible fatal risk, most patients are being treated in hospitals. The initial treatment was to interrupt platelet activation induced by VITT antibody, using blood thinner(usually non heparin thinner) and IV immunoglobulin. The use of corticosteroids can reduce abnormal immune system responses. Medical cases may require plasma exchange and additional immune drugs. It is important to monitor the platelet value every day and check almost all signs of thrombosis clinically. Many cases continue to light up, they are no longer vulnerable, platelet count stability after discharge.